TransEnterix (NYSEMKT: TRXC), an upstart robotic-surgery company, saw its shares gain a stellar 22.7% in July, according to data from S&P Global Market Intelligence. The spark?TransEnterix's shares heated up following a corporate update early in the month. Most importantly, the company noted that it had sold four of its Senhance Systems during the second quarter, implying that the product's commercial launch was continuing to gain momentum. Management also reiterated that the FDA had granted a lucrative label expansion earlier in the quarter for the system covering patients undergoing laparoscopic inguinal hernia and laparoscopic gallbladder removal surgery. Image source: Getty Images.Continue reading